Taken together, our study proves that while a series of studies have confirmed the predictive role of FAT3 and LRP1B mutations in tumor immunotherapy, the results of genetic testing found that LUAD patients with FAT3 or LRP1B mutations may not necessarily benefit from immunotherapy, only the LUAD population with both FAT3 and LRP1B mutations can benefit from ICIs therapy. The gene discussed is LRP1B; the disease is neoplasm.